HUE043473T2 - Fokozott immunválasz szarvasmarha fajokban - Google Patents

Fokozott immunválasz szarvasmarha fajokban

Info

Publication number
HUE043473T2
HUE043473T2 HUE11804675A HUE11804675A HUE043473T2 HU E043473 T2 HUE043473 T2 HU E043473T2 HU E11804675 A HUE11804675 A HU E11804675A HU E11804675 A HUE11804675 A HU E11804675A HU E043473 T2 HUE043473 T2 HU E043473T2
Authority
HU
Hungary
Prior art keywords
immune response
increased immune
bovine species
bovine
species
Prior art date
Application number
HUE11804675A
Other languages
English (en)
Inventor
Albert Abraham
Daniel Keil
Jason Nickell
Christian Weiss
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of HUE043473T2 publication Critical patent/HUE043473T2/hu
Publication of HUE043473T4 publication Critical patent/HUE043473T4/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE11804675A 2010-12-22 2011-12-20 Fokozott immunválasz szarvasmarha fajokban HUE043473T4 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061426255P 2010-12-22 2010-12-22

Publications (2)

Publication Number Publication Date
HUE043473T2 true HUE043473T2 (hu) 2019-08-28
HUE043473T4 HUE043473T4 (hu) 2019-12-30

Family

ID=45444595

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11804675A HUE043473T4 (hu) 2010-12-22 2011-12-20 Fokozott immunválasz szarvasmarha fajokban

Country Status (35)

Country Link
US (3) US20130295167A1 (hu)
EP (1) EP2654785B1 (hu)
JP (2) JP6058550B2 (hu)
KR (1) KR101940826B1 (hu)
CN (2) CN108379576A (hu)
AR (1) AR084510A1 (hu)
AU (1) AU2011347464B2 (hu)
BR (1) BR112013016231B1 (hu)
CA (1) CA2822359C (hu)
CL (1) CL2013001833A1 (hu)
CO (1) CO6761354A2 (hu)
CR (1) CR20130312A (hu)
DK (1) DK2654785T3 (hu)
DO (1) DOP2013000149A (hu)
EC (1) ECSP13012709A (hu)
ES (1) ES2722204T3 (hu)
GT (1) GT201300168A (hu)
HK (1) HK1259341A1 (hu)
HR (1) HRP20190779T1 (hu)
HU (1) HUE043473T4 (hu)
IL (1) IL226733B (hu)
LT (1) LT2654785T (hu)
MX (1) MX345854B (hu)
MY (1) MY167159A (hu)
NZ (1) NZ612285A (hu)
PH (1) PH12013501348B1 (hu)
PL (1) PL2654785T3 (hu)
PT (1) PT2654785T (hu)
RU (1) RU2606855C2 (hu)
SI (1) SI2654785T1 (hu)
TR (1) TR201906323T4 (hu)
TW (1) TWI587877B (hu)
UA (1) UA118537C2 (hu)
UY (1) UY33821A (hu)
WO (1) WO2012084951A1 (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2654785T3 (da) * 2010-12-22 2019-06-24 Bayer Ip Gmbh Forøget immunrespons hos kvægracer
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP3110940A1 (en) 2014-02-28 2017-01-04 Bayer Animal Health GmbH Immunostimulatory plasmids
CN104825393B (zh) * 2015-01-16 2017-11-10 艾美科健(中国)生物医药有限公司 一种硫酸头孢喹肟肺靶向脂质体制剂及其制备方法
US20190233825A1 (en) * 2015-06-26 2019-08-01 Bayer Animal Health Gmbh Methods of modulating cytosolic dna surveillance molecules
CN108712912B (zh) * 2015-07-31 2022-05-10 拜耳动物保健有限责任公司 在水生物种中增强的免疫应答
TW201718001A (zh) * 2015-07-31 2017-06-01 拜耳動物保健有限公司 豬物種中增強之免疫反應
EP3490598A1 (en) * 2016-07-26 2019-06-05 Bayer Animal Health GmbH Increased fertility in bovine species
KR102069680B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역억제인자 제어물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
CN111801419A (zh) * 2017-12-15 2020-10-20 拜耳动物保健有限责任公司 免疫刺激性寡核苷酸
CN108812546A (zh) * 2018-09-07 2018-11-16 四川省草原科学研究院 适于青藏高原地区牦牛运输减少应激的药物及使用方法
CN109646435B (zh) * 2019-01-11 2021-08-03 山东省农业科学院奶牛研究中心 厄他培南钠在制备防治牛传染性鼻气管炎药物中的应用
WO2020194735A1 (ja) 2019-03-28 2020-10-01 日本電気株式会社 情報処理装置、サーバ割当装置、方法、及びコンピュータ可読媒体
CN114480663A (zh) * 2021-11-15 2022-05-13 贵州省畜牧兽医研究所 用于检测猪源差异脲原体的引物对、试剂盒及检测方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5427791A (en) 1992-08-05 1995-06-27 Regents Of The University Of Minnesota Embryonal vaccine against Newcastle disease
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5830878A (en) * 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6048535A (en) 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
EP1955709B1 (en) 1999-03-26 2012-03-14 Vical Incorporated Adjuvant compositions for enhancing immune responses to polynucleotide-based vaccines
RU2158587C1 (ru) * 1999-05-11 2000-11-10 Ставропольское научно-производственное объединение "Пульс" Антибактериальное средство для лечения заболеваний сельскохозяйственных животных и птиц, способ профилактики и лечения цыплят при заболеваниях бактериальной этиологии, способ лечения респираторной болезни телят бактериальной этиологии, способ профилактики туберкулеза у крупного рогатого скота
US20040002472A1 (en) * 2000-01-21 2004-01-01 Audonnet Jean-Christophe Francis Vaccination or immunization using a prime-boost regimen
PE20020572A1 (es) * 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
JP4261195B2 (ja) 2001-04-24 2009-04-30 イノジェネティックス・ナムローゼ・フェンノートシャップ 酵母のコア−グリコシル化されたhcvエンベロープタンパク質の発現
WO2003004051A2 (en) * 2001-07-02 2003-01-16 Pfizer Products Inc. Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle
NZ542652A (en) * 2003-03-26 2008-04-30 Wyeth Corp Immunogenic composition and methods
PE20050386A1 (es) * 2003-05-29 2005-06-23 Schering Plough Ltd Composiciones farmaceuticas de florfenicol
JP2007509040A (ja) * 2003-10-11 2007-04-12 イネックス ファーマシューティカルズ コーポレイション 先天性免疫及び抗体依存性細胞傷害を強化するための方法及び組成物
UY29915A1 (es) 2005-11-15 2007-06-29 Boehringer Ingelheim Vetmed Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina
JP2008094763A (ja) * 2006-10-12 2008-04-24 Takeshi Ogura 海洋ミネラル成分からなるインターフェロンγ産生増強剤
US20110111017A1 (en) * 2008-02-24 2011-05-12 Government Of The United States Of America,As Rep. By The Secretary,Dept. Of Health And Human Servic Use of immunogenic compositions for the treatment or prevention of pathogen infections
CA2719614C (en) * 2008-03-25 2018-05-01 Juvaris Biotherapeutics, Inc. Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc)
EP2362780B1 (en) * 2008-10-31 2019-12-25 Boehringer Ingelheim Animal Health USA Inc. Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
SI2992899T1 (sl) 2009-05-14 2020-10-30 Bayer Intellectual Property Gmbh Povečan imunski odziv pri ptičjih vrstah
DK2654785T3 (da) * 2010-12-22 2019-06-24 Bayer Ip Gmbh Forøget immunrespons hos kvægracer

Also Published As

Publication number Publication date
CN108379576A (zh) 2018-08-10
PH12013501348B1 (en) 2019-11-22
HRP20190779T1 (hr) 2019-06-28
HUE043473T4 (hu) 2019-12-30
CA2822359A1 (en) 2012-06-28
UA118537C2 (uk) 2019-02-11
CN103501810A (zh) 2014-01-08
CO6761354A2 (es) 2013-09-30
NZ612285A (en) 2015-09-25
ES2722204T3 (es) 2019-08-08
DK2654785T3 (da) 2019-06-24
MX345854B (es) 2017-02-17
PL2654785T3 (pl) 2019-09-30
DOP2013000149A (es) 2013-08-15
KR101940826B1 (ko) 2019-01-21
WO2012084951A1 (en) 2012-06-28
GT201300168A (es) 2015-02-23
ECSP13012709A (es) 2013-08-30
US20130295167A1 (en) 2013-11-07
MX2013007064A (es) 2013-08-21
TWI587877B (zh) 2017-06-21
JP2017036290A (ja) 2017-02-16
SI2654785T1 (sl) 2019-06-28
RU2013133730A (ru) 2015-01-27
AU2011347464B2 (en) 2016-08-25
MY167159A (en) 2018-08-13
CL2013001833A1 (es) 2014-06-20
TW201306877A (zh) 2013-02-16
KR20130132926A (ko) 2013-12-05
JP6058550B2 (ja) 2017-01-11
BR112013016231B1 (pt) 2021-03-23
IL226733B (en) 2020-06-30
RU2606855C2 (ru) 2017-01-10
AU2011347464A1 (en) 2013-07-11
AR084510A1 (es) 2013-05-22
PT2654785T (pt) 2019-06-25
JP2014500292A (ja) 2014-01-09
CA2822359C (en) 2021-06-01
US10751361B2 (en) 2020-08-25
CR20130312A (es) 2013-10-17
PH12013501348A1 (en) 2013-08-28
BR112013016231A2 (pt) 2016-09-27
AU2011347464A2 (en) 2013-08-22
US20190201434A1 (en) 2019-07-04
EP2654785B1 (en) 2019-03-20
EP2654785A1 (en) 2013-10-30
HK1259341A1 (zh) 2019-11-29
US20140010865A1 (en) 2014-01-09
LT2654785T (lt) 2019-07-10
TR201906323T4 (tr) 2019-05-21
UY33821A (es) 2012-07-31

Similar Documents

Publication Publication Date Title
HUE043473T4 (hu) Fokozott immunválasz szarvasmarha fajokban
DK2605335T3 (da) Tilslutningsklemme
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
EP2705844A4 (en) FOOD COMPOSITION
IL231777B (en) Antibodies against tl1a and uses thereof
EP3542638C0 (en) Nutritional composition
EP2721512A4 (en) CONTEXTIC INTERACTION
DK3421470T3 (da) Substituerede 5-fluor-1h-pyrazolopyridiner i krytallinsk form
CO6870003A2 (es) Vacunas bovinas y métodos
PT2665818T (pt) Expressão de proteínas em plantas
ME02224B (me) Antikancerski fuzioni protein
DK2992899T3 (da) Forøget immunrespons hos fuglearter
DK2721152T3 (da) Dimere bindingsproteiner baseret på modificerede ubiquitiner
DK2704744T3 (da) Komplementfaktor-b-analoger og anvendelser deraf
BR112013018397A2 (pt) suplemento equino nutricional
ES1072644Y (es) Botiquin inteligente
DK2672837T4 (da) Ernæringssammensætning og anvendelser deraf
EP2733361A4 (en) TURBO COMPRESSOR
UY4077Q (es) Configuración aplicada en calzado
EP2728198A4 (en) TURBO COMPRESSOR
FI20100398A7 (fi) Menetelmä polttouunissa
UY3960Q (es) Configuración aplicada en licuadora
IT1403676B1 (it) Manufatti in ferrolega
FI20115819L (fi) Järjestely hississä
UY4071Q (es) Configuración aplicada en triciclo